107 results on '"Baker, Dawn"'
Search Results
2. supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
3. Supplementary Methods, Figure Legend from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo
4. Data from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
5. supplementary Table 6 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
6. supplementary figure and table legend from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
7. Data from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
8. supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
9. supplementary Table 3 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
10. supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
11. Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
12. supplementary figure and table legend from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
13. Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
14. supplementary Table 3 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
15. supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
16. supplementary Table 6 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
17. supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
18. supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
19. supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
20. Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
21. Supplementary Figure 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
22. Supplementary Table 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
23. Supplementary Table 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
24. Supplementary Table 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
25. Supplementary Figure Legend from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
26. Supplementary Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
27. Supplementary Table 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
28. Supplementary Figure 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
29. Supplementary Table 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
30. Supplementary Table 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
31. Supplementary Figure 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
32. Supplementary Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
33. Supplementary Figure 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
34. Supplementary Figure Legend from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
35. Supplementary Figure 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
36. Supplementary Figure 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
37. Supplementary Table 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
38. Supplementary Figure 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
39. Supplementary Table 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
40. Supplementary Figure 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
41. Data from AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
42. Supplementary Table 1 from AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
43. Supplementary Table 1 from AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
44. Supplementary Figure Legends 1-2 from AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
45. Supplementary Figure 2 from AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
46. Supplementary Figure 1 from AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
47. Supplementary Figure 2 from AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
48. Supplementary Figure Legends 1-2 from AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
49. Supplementary Figure 1 from AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
50. Data from AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.